Dr. Klein on the Importance of the Importance of Prognostic Genomic Assays in Prostate Cancer

Prognostic value of the SPOP mutant genomic subclass in prostate cancerПодробнее

Prognostic Factors in Prostate Cancer: Gleason Scores, PSA Levels, and Genomic TestingПодробнее

Genomic Testing Impacts Treatment Decisions in Prostate CancerПодробнее

Dr. Klein on Precision Medicine for Prostate CancerПодробнее

Genomic testing: a precision-medicine approach applied to early-stage prostate cancerПодробнее

Point-Counterpoint Q&A w/ Dr. Klein: Oncotype Dx Genomic Prostate Score in Active SurveillanceПодробнее

Importance of Genomic Testing for Patients With Metastatic Prostate CancerПодробнее

Genetic Testing For Prostate Cancer | BRCA | #MarkScholzMD #AlexScholz #PCRIПодробнее

Prolaris - Not All Cancers Are the SameПодробнее

Genomic testing in prostate cancerПодробнее

Dr. Christopher Barbieri - Genomic Testing For Prostate Cancer PatientsПодробнее

Dr. Jeffrey Tomaszewski: The application of prostate cancer genomic testsПодробнее

Genomic Testing and Prostate Cancer: The Role of the UrologistПодробнее

Diagnostic and Prognostic BiomarkersПодробнее

Role of genomic profiling in the management of intermediate-risk prostate cancerПодробнее

Clinicopathologic models in prostate cancer: impact of a 22-gene genomic classifierПодробнее

Dr. Katz on the Oncotype DX GPS Assay in Prostate CancerПодробнее

Liquid Biopsy for Early Detection of Prostate Cancer with Eric Klein, MD [EP 107]Подробнее

Dr. Klein on Gene Mutations in Prostate CancerПодробнее